KRAS G12C is the most common form of KRAS mutation ... hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market. Join the conversation, on Tuesday 28th January @ 10 am ...

FDA approves a new treatment for KRAS G12C-mutated metastatic colorectal cancer, showing significant progression-free ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...